Ceftriaxone and Jaundice in Neonates

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

27 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-03-31

Study Completion Date

2019-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Ceftriaxone is an antibiotic often used for the management of sepsis. Neonates commonly have jaundice during the first postnatal week. Ceftriaxone will be given as standard of care for sepsis and investigators will observe the effect on jaundice.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age

NCT05856227

Neonatal Sepsis

COMPLETED PHASE3

Antibiotic Therapy for Early Onset Neonatal Sepsis

NCT03932123

Early Onset Neonatal Sepsis

RECRUITING

An Open Label Study to Describe the Pharmacokinetics of Cefazolin in Preterm Neonates

NCT00850122

Sepsis Prematurity

COMPLETED PHASE1

Antibiotic Stewardship to Prevent Early Sepsis in Preterm Infants

NCT06930911

Prematurity, Infections

ACTIVE_NOT_RECRUITING

A Pilot Randomized Controlled Trial for Antibiotic Exposure in Neonatal Sepsis Using Neutrophil CD64

NCT01825421

Neonatal Early-onset Sepsis Neonatal Late-onset Sepsis

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Jaundice and Sepsis in Neonates

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ceftriaxone Arm

ceftriaxone

Intervention Type DRUG

Eligible infants will receive ceftriaxone as standard of care for sepsis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ceftriaxone

Eligible infants will receive ceftriaxone as standard of care for sepsis

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Term infants with sepsis requiring IV antibiotics for more than 3 days and who has total serum bilirubin 6-12 mg/dL and resolving by day 4 of life.

Exclusion Criteria

* Infants with asphyxia (Apgar score \<3 at 5 minutes), chromosomal disorder, failed hearing test at baseline, family history of hearing loss, unconjugated hyperbilirubinemia requiring phototherapy, TORCH infection, craniofacial malformations, listeria monocytogenes infection, and any clinical conditions which will preclude discharge to home.

Minimum Eligible Age

3 Days

Maximum Eligible Age

7 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

No